Wet Macular Degeneration

Ophthalmology
6
Pipeline Programs
5
Companies
7
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Regeneron
EYLEAApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2011
Regeneron
EYLEA HDApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2023

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
5 programs
1
AfliberceptPhase 4
AfliberceptN/A
AfliberceptN/A
AfliberceptN/A
AfliberceptN/A
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
1
1
BI 144807Phase 21 trial
BI 836880Phase 1/21 trial
Active Trials
NCT03861234Completed43Est. Nov 2023
NCT02121522Completed14Est. Apr 2015
Sylentis
SylentisSpain - Madrid
1 program
1
SYL1801Phase 21 trial
Active Trials
NCT05637255UnknownEst. Nov 2023
Bayer
BayerLEVERKUSEN, Germany
3 programs
AfliberceptN/A1 trial
AfliberceptN/A1 trial
Anti-VEGF injectionsN/A1 trial
Active Trials
NCT02279537Completed593Est. Apr 2019
NCT02321241Completed236Est. Aug 2017
NCT01448538Completed480Est. Feb 2014
Thea Pharma
Thea PharmaMA - Waltham
1 program
RetilutN/A1 trial
Active Trials
NCT04756310CompletedEst. Apr 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SylentisSYL1801
Boehringer IngelheimBI 144807
Boehringer IngelheimBI 836880
BayerAflibercept
Thea PharmaRetilut
BayerAflibercept
BayerAnti-VEGF injections

Clinical Trials (7)

Total enrollment: 1,366 patients across 7 trials

NCT05637255SylentisSYL1801

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Start: Nov 2022Est. completion: Nov 2023
Phase 2Unknown
NCT02121522Boehringer IngelheimBI 144807

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Start: Jun 2014Est. completion: Apr 201514 patients
Phase 2Completed
NCT03861234Boehringer IngelheimBI 836880

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Start: Jun 2019Est. completion: Nov 202343 patients
Phase 1/2Completed
NCT02321241BayerAflibercept

Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

Start: Feb 2016Est. completion: Aug 2017236 patients
N/ACompleted
NCT04756310Thea PharmaRetilut

Study of Nutritional Supplementation in Patients With Unilateral Wet AMD

Start: Nov 2014Est. completion: Apr 2018
N/ACompleted
NCT02279537BayerAflibercept

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Start: Jan 2014Est. completion: Apr 2019593 patients
N/ACompleted
NCT01448538BayerAnti-VEGF injections

Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany

Start: Aug 2011Est. completion: Feb 2014480 patients
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)